Since 1973 Stella Maris Foundation is the only Scientific Institute for Research Hospitalization and Health Care (IRCCS in Italy exclusively dedicated to research and assistance in Child Neurology and Psychiatry, a discipline of important scientific impact in clinical neurosciences of a great social relevance. It is an advanced research hospital that combines the highest levels of care with a very high quality of scientific research in developmental neuroscience. Rare diseases, intellectual disabilities, autism, neurological disorders, movement disorders, ADHD are some of the pathologies studied and treated at Stella Maris. The Hospital Centre, situated in Calambrone (Pisa), organized in a multi-professional way, is an internationally recognized hub that involves the activity of university professors and researchers.

The Foundation also acts as a teaching centre for the University of Pisa and hosts the School of Specialization in Child Neurology Psychiatry and the Degree Course for Developmental Therapists.

It hosts and is one of the founders of IMAGO7 Foundation, a research centre developed around an Ultra High Field Magnet Resonance System (MR 7Tesla, the only one in Italy) aimed at the development of interdisciplinary research in neuroscience and clinical imaging.

Since 1959, Gaslini hospital has been formally recognized as a Scientific Institute for Treatment and Research (Istituto di Ricovero e Cura a Carattere Scientifico, IRCCS).

Today, Gaslini is an hospital with a scientifically-minded outlook at international level.

In the healthcare offer you will find all pediatric and surgical specialties at the highest levels of expertise.

The scientific laboratories and the affiliated Universities, many of which have their own Residency Schools and Advanced Courses, are also of the highest level.

Bambino Gesù Children’s Hospital (OPBG) is the largest Hospital and Institute for Treatment and Research in Europe. All pediatric specialties are represented, distributed within the 5 venues of the Hospital.
Meeting the International standards of excellence in the welcome and quality of care, in 2006 the Hospital was accredited by Joint Commission International.
Since 2015, Bambino Gesù Children’s Hospital has been accredited by JCI as "Academic Hospital", after the evaluation of the quality of training and clinical research, meeting the management and administrative requirements.
The Hospital is the headquarter of the Residency Schools of Pediatrics and Pediatric Surgery of the University of Rome Tor Vergata and of the Post Graduate School of Pediatrics, which provides training courses such as Masters and Advanced Courses of high professional qualification.

Pedianet is an independent network of family paediatricians established in 1998 to collect information from outpatient family paediatricians in Italy for clinical and epidemiological research (e.g., pharmacovigilance studies, studies on prescribing patterns, and studies of the efficiency of health services). The Pedianet database’s beginning dates back to January 2000. The Pedianet system has the advantage of collecting data at a population level as a by-product of routine activities, therefore generating a far larger quantity of data than ad hoc studies

Meyer Children's Hospital (a "research hospital" (IRCCS) recognized by the Italian Ministry of Health) is a highly specialized 250-bed hospital equipped with all of the pediatric medical and surgical specialties.  Meyer is part of the Italian National Health Service and, in particular, of the Tuscan health system.  It is integrated with the University of Florence, with which it carries out healthcare, training and research activities.

The Italian Society of Pharmacology (SIF) is a non-profit scientific association aimed at promoting basic, applied, and clinical pharmacology research. The Working Groups in Pediatric Pharmacology and Rare Diseases and Orphan Drugs, operating within the SIF, bring together various biomedical and pharmacological skills of pre-clinical and clinical research in pediatrics and rare diseases, contributing to overcome critical issue across efficacy, safety, access and sustainability of pharmacotherapies in these areas.

Penta is an international independent scientific network dedicated to child health. We are at the forefront of clinical research because we aim to improve the prevention, diagnosis and treatment of infections in children. Through our studies and our training program, we support health systems around the world to treat children in the best possible way. Our scientific excellence is the result of the dedication of our Network of researchers and doctors active in more than 110 centers in 31 countries around the world.

The Institute has been recognized as I.R.C.C.S. since 10 December 1968. The I.R.C.C.S. Burlo Garofolo presents itself as a highly specialized hospital of national importance in the pediatric sector and in dealing with maternity and women's health. It pursues research in the biomedical field and the organization of health services, innovation of assistance models and knowledge transfer. It provides highly qualified hospitalization and care services to minors, pregnant women, newly born women and women with gynaecological pathologies to Italian and foreign citizens. The research activity at Burlo Garofolo is conducted in the areas of reproductive health, maternal-fetal medicine, neonatology, genetically transmitted diseases and chronic and tumour diseases with onset in pediatric age, general and specialist pediatric surgery, anesthesiology pediatric, developmental neuroscience, gynaecology, and extends to the epidemiology of environmental, infectious and lifestyle factors relevant to the health of mothers, children and adolescents and operational research on health services. The research draws objectives and stimuli from clinical and epidemiological activity. It aims to transfer the product of new knowledge, new technologies and new care models to the entire regional and national health service and the international scientific community. This activity translates into more than a hundred publications annually in journals of the highest scientific prestige in their respective fields. The research product is also characterized by its potential to produce short and medium-term effects on the National Health Service.

Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF) is a non-profit research organization founded in 2000 with the mission of facilitating and accelerating the development of drugs with a particular focus on those aimed at the paediatric population and those with rare diseases. CVBF is recognized in Europe for its specific expertise on paediatric and rare disease issues, gained as coordinator/partner in research projects FP6, FP7, H2020, and Horizon Europe, in particular aimed at carrying out multinational trials and creating stable research networks/infrastructures to contribute to the many unmet therapeutic needs plaguing patients with paediatric and rare diseases. Furthermore, CVBF, as a Clinical Research Organization (CRO), supports the success of each phase of drug development by creating value for all the stakeholders involved, combining flexibility, quality and experience with innovative scientific and methodological approaches.

IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico, known simply as Policlinico of Milan, since it was founded in 1456, it has followed the patients in their path of healing, affecting the History of medicine and anticipating various innovations that are revolutionary to this day.

The Policlinico’s mission has always been oriented towards integrating care with research and training. This allows us to offer the best health care at every age of life, from the stages preceding conception to adulthood.

AIEOP is a scientific assoxiation accredited by the Ministry of Health, operating throughout Italy with 49 affiliated centers and about 750 members among healthcare professionals.

AIEOP's main purpose is promoting research and care activities in the field of pediatric hematology and oncology, as well as developing and coordinating treatment protocols, disseminating knowledge, facilitating national and international collaborations and stimulating synergies between associations.

To guarantee quality of care, AIEOP centers are identified according to specific qualitative, structural, technological and quantitative requirements and they adopt common treatment protocols.

AIEOP's headquarters is based in Bologna. It oversees the Database and supports their activities.

Every year about 2,300 cases, including new diagnoses, bone marrow transplants and immunodeficiencies, are registered with a unique identifier. To date, more than 65,000 cases have been reported.

The history of AIEOP starts in 1971, from the drafting of the first Italian protocol for the treatment of pediatric acute leukemia, which is no longer an incurable disease.

The Italian Association of Pediatric Immunology and Oncology was born in 1975. Then, in 1985, it took on the new name of the Italian Association of Pediatric Hematology and Oncology (AIEOP). The Association deals with leukemia, childhood cancers and non-tumor haematological diseases by drawing up protocols and guidelines.

Since 1989, all new cases of cancer diagnosed in AIEOP centers have been registered. AIEOP is the first pediatric hemato-oncology association in the world to create a database, which became electronic in 2000. The analysis of the results of the care protocols allows for the identification of appropriate improvements to be implemented in the next protocol.